Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Boehringer Ingelheim
Colorcon
Express Scripts

Last Updated: September 26, 2022

Details for Patent: 8,580,304


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,580,304 protect, and when does it expire?

Patent 8,580,304 protects MEKINIST and is included in one NDA.

This patent has thirty-nine patent family members in thirty-three countries.

Summary for Patent: 8,580,304
Title:Pharmaceutical composition
Abstract: Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-tr- ioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.
Inventor(s): DeMarini; Douglas J. (Collegeville, PA), Henriquez; Francisco (Collegeville, PA), Le; Ngocdiep T. (Collegeville, PA), Wang; Lihong (Collegeville, PA)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:13/330,949
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process;

Drugs Protected by US Patent 8,580,304

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-001 May 29, 2013 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-002 May 29, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-003 May 29, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,580,304

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 084102 See Plans and Pricing
Australia 2011349422 See Plans and Pricing
Brazil 112013015602 See Plans and Pricing
Canada 2822701 See Plans and Pricing
Chile 2013001779 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Baxter
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.